MedTrace Logo

China PEACE-Retrospective CathPCI Study

NCT01624896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12000

Last updated 2014-07-01

No results posted yet for this study

Summary

Coronary heart disease (CHD) is one of the leading causes of mortality and morbidity. PCI, as a well-proved and booming measure in CHD management, is invasive and of high cost, however the knowledge about the real-life PCI use in China is limited. Within a nation-wide and regional representative probability sample of hospitals in China, 14,000 CAG/PCI inpatient cases will be sampled randomly from 2001 to 2011. The sampled medical records will be reviewed and abstracted in the national coordinating centre, in order to evaluate the treatment pattern, outcomes, and cost for PCI, during the past decade. Basic data and innovative evidence will accelerate evidence-based clinical practice and policy making, and improve patients outcomes in future finally.

Conditions

Sponsors & Collaborators

  • Ministry of Health, China

    collaborator OTHER_GOV

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Lixin Jiang, M.D., Ph.D. · China National Center for Cardiovascular Diseases

  • Harlan M Krumholz, M.D., S.M. · Yale University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-10-31
Completion
2013-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01624896 on ClinicalTrials.gov